Biocon Corporate Presentation
Generics: Investing into capacities and capabilities
for the future growth
-TH
罩
$
Biocon
Differentiated API business
5 state-of-the-art facilities across Bangalore,
Hyderabad and Visakhapatnam in India to
manufacture high quality products with
reliability and efficiency.
Expertise in fermentation technology, large scale
chromatography and synthetic chemistry gives
us a key competitive edge in APIs.
Among the world's largest manufacturers of
immunosuppressant and statin APIs
1,000+ customers in 100+ countries including the
U.S, Europe and large emerging markets, with a
track-record of excellence for over 20 years.
223 1000+
Customers
ה ווווי
Growing Formulations Footprint
Solid oral & parenteral products in both potent &
non-potent categories
Focus therapeutic segments - Metabolics,
Oncology, Immunology & Auto-immune
indications
Generic Tacrolimus, Rosuvastatin, Simvastatin &
Atorvastatin launched in the United States
Entered partnerships to expand Generic
Formulations footprint in China, Singapore,
Thailand
Regulatory licenses received from MHRA for
import and distribution of our formulations in UK
280+
Patents Obtained
50%
Global MS in orlistat API
& world's leaders in
immunosuppressants
Investments for future growth
Expanding our R&D capabilities for newer
fermentation-derived and chemical synthesis-
based molecules.
Focus on developing niche, difficult-to-make,
complex molecules with relatively higher entry
barriers.
Investing Rs. 6 billion in greenfield,
fermentation-based manufacturing facility in
Visakhapatnam, Andhra Pradesh
Focus on adopting best-in-class quality practices
and implement digital processes in our quality
and related functions
Retaining leadership in key APIs with structured
cost improvement programs
800+
Metric ton cumulative
weight of APIs supplied
annually
10View entire presentation